These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 22934764)

  • 1. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
    Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
    Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based drug design: computational & experimental state of the art.
    Hoffer L; Renaud JP; Horvath D
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):500-20. PubMed ID: 21521152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
    Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
    Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using computational techniques in fragment-based drug discovery.
    Desjarlais RL
    Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based lead discovery on G-protein-coupled receptors.
    Visegrády A; Keserű GM
    Expert Opin Drug Discov; 2013 Jul; 8(7):811-20. PubMed ID: 23621346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspectives in fragment-based lead discovery (FBLD).
    Lamoree B; Hubbard RE
    Essays Biochem; 2017 Nov; 61(5):453-464. PubMed ID: 29118093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery.
    Gozalbes R; Carbajo RJ; Pineda-Lucena A
    Curr Med Chem; 2010; 17(17):1769-94. PubMed ID: 20345344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment screening for drug leads by weak affinity chromatography (WAC-MS).
    Ohlson S; Duong-Thi MD
    Methods; 2018 Aug; 146():26-38. PubMed ID: 29378316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer using fragment based drug discovery.
    Turnbull AP; Boyd SM
    Anticancer Agents Med Chem; 2012 Jan; 12(1):40-8. PubMed ID: 21707503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.